. 2016 Aug 16;4:48. doi: 10.1186/s40425-016-0153-x

Table 1.

Response rates to anti-PD-1 and overall survival in NSCLC by study

Study	Histology	Treatment	# patients	ORR (%)	Median response duration (months)	OS (months)
Nivolumab
Gettinger et al. [11]^a	All	Nivolumab 3 mg/kg q2wks	37	24.3	17	14.9
Gettinger et al. [11]^a	All	Nivolumab 10 mg/kg q2wks	59	20.3	19.1	9.2
Rizvi et al. [13] (CHECKMATE 063)	Squamous	Nivolumab 3 mg/kg q2wks	117	14.5	Not reached	8.2
Brahmer et al. [14] (CHECKMATE 017)	Squamous	Nivolumab 3 mg/kg q2wks	135	20	Not reached	9.2
Brahmer et al. [14] (CHECKMATE 017)	Squamous	Docetaxel 75 mg/m² q3wks	137	9	8.4	6
Borghaei et al. [15] (CHECKMATE 057)	Non-squamous	Nivolumab 3 mg/kg q2wks	292	19	17.2	12.2
Borghaei et al. [15] (CHECKMATE 057)	Non-squamous	Docetaxel 75 mg/m² q3wks	290	12	5.6	9.4
Bauer et al. [55]	All	Nivolumab 3 mg/kg q 2wks	51	13.7	Not reported	Not reported
Pembrolizumab
Garon et al. [16] (KEYNOTE 001)	All	Pembrolizumab 2 mg/kg q3wks	6	33.3	12.5	9.3 (prior therapy)
		Pembrolizumab 10 mg/kg q3wks	287	19.2		9.3 (prior therapy)
		Pembrolizumab 10 mg/kg q3wks	287	19.2		16.2 (no prior therapy)
		Pembrolizumab 10 mg/kg q2wks	202	19.3		16.2 (no prior therapy)
Herbst et al. [17] (KEYNOTE 010)	All	Pembrolizumab 2 mg/kg q3wks	344	18	Not reached	10.4
		Pembrolizumab 10 mg/kg q3wks	346	18.5	Not reached	12.7
		Docetaxel 75 mg/m² q3wks	343	9.3	6	8.5

^aCohorts receiving doses lower than 3 mg/kg were omitted from the table due to low response rates